SCHEMBL27195688

SCHEMBL27195688

CN1CCN(c2ccc(C(=O)Nc3cccc4cnccc34)cc2F)CC1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 6/20 0.57
▸ CNR1 P21554 1/20 0.54
▸ WDR5 P61964 6/20 0.53
▸ BRD4 O60885 1/20 0.51
▸ JAK1 P23458 1/20 0.51
▸ FGFR1 P11362 1/20 0.46
▸ FGFR2 P21802 1/20 0.46
▸ NPY5R Q15761 1/20 0.46
▸ POLB P06746 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ MAPT P10636 2/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ GALK1 P51570 1/20 0.45
▸ ATM Q13315 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30863450 1.00 TRPV1 (0.57) TRPV1CNR1WDR5BRD4JAK1
SCHEMBL27195706 0.84 TRPV1 (0.58) TRPV1CNR1MAPK1
SCHEMBL27195727 0.84 CNR1 (0.53) TRPV1CNR1NPY5RMAPK1MAPT
SCHEMBL30863422 0.79 WDR5 (0.49) WDR5FGFR1FGFR2MAPT
SCHEMBL27195721 0.78 SIRT6 (0.55) TRPV1CNR1NPY5RMAPTALDH1A1
Hydrochloric Acid SCHEMBL30863459 0.76 CNR1 (0.57) TRPV1CNR1NPY5RMAPK1MAPT
SCHEMBL27195713 0.76 HDAC6 (0.60) TRPV1CNR1MAPK1MAPTKDM4E
SCHEMBL27195758 0.76 AURKA (0.53) —
SCHEMBL30863515 0.75 TRPV1 (0.59) TRPV1NPY5RMAPTALDH1A1SMN1; SMN2
SCHEMBL30863517 0.75 CNR1 (0.51) TRPV1CNR1MAPTKDM4EGALK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4353712-A1 NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS Biodol Therapeutics (FR) 2024-04-17 — — EP claimed
EP-4353712-A1 NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS Biodol Therapeutics (FR) 2024-04-17 — — EP disclosed
Send feedback